Protocol Deviations

March 2017 Training



Overview of Today's Discussion

- Key resources
- Definitions
- Policy requirements for protocol deviations considered reportable by IMPAACT ("reportable deviations")
- Procedures for reportable deviations
- Scenarios
- Questions

Key Resources


IMPAACT Manual of Procedures, Section 12.4, Protocol Deviations

http://impaactnetwork.org/DocFil es/MOP/12 Implementation.pdf


Definitions

Protocol deviation	Any departure from an IRB-approved protocol
Reportable protocol deviation	 Deviations that require additional reporting by the IoR or designee as described in Section 12.4.3. Defined by IMPAACT as deviations that result in: Significant increased risk to the study participants or others Significant non-compliance with IRB-approved protocol requirements Significant non-compliance with Good Clinical Practices or Good Clinical Laboratory Practices and all applicable regulations

Deviations, Violations, Critical Events... Oh My!



Deviations, Violations, Critical Events... Oh My!



Protocol deviations may include ...

- Administrative inconsistencies or minor study implementation errors (e.g., visit or procedure performed outside of window)
- Departure from specified treatment, examination, data collection, or reporting procedures
- Violation of inclusion/exclusion criteria

Protocol Deviations

- Deviations may or may not render a participant ineligible and may be considered significant or serious when they increase potential risk to participants or affect the integrity of study data
- An isolated deviation may not be significant by itself but significance may increase with numerous deviations of the same nature

Examples of Protocol Deviations

- Hair collection for study drug levels was missed in error for participant who was off treatment/on study
- Infant's washout PK sampling was obtained within the specified window but it was not possible to perform a physical exam within the window
- Procedures required to be performed within 48 hours of birth were performed between 49 and 50 hours of birth

Protocol Deviations

- All protocol deviations must be adequately documented in study records consistent with DAIDS SOPs for source and essential documentation, including
 - Description of the deviation
 - Reasons why it occurred
 - Corrective and preventive actions taken in response

https://www.niaid.nih.gov/research/daids-clinical-site-implementation-operations

Protocol Deviations

 Deviations must also be reported to site IRBs/ECs and other regulatory entities, following their policies and procedures

Now let's look at protocol deviations defined as <u>reportable</u> by IMPAACT ...

Reportable Protocol Deviations

Protocol deviations are reportable to the IMPAACT Network if they result in

- <u>Significant</u> increased risk to participants or others
- <u>Significant</u> non-compliance with IRB-approved protocol requirements
- <u>Significant</u> non-compliance with GCP or GCLP and all applicable regulations

Participant Non-Compliance

- Participant non-compliance (e.g., participant misses study visits or does not take study drug) is considered a protocol deviation but is not considered a reportable protocol deviation
- Participant non-compliance should be documented and reported per usual site procedures (and any applicable protocol requirements) but should not be reported to the Network

Examples of <u>Reportable</u> Protocol Deviations (1)


- Enrollment of an ineligible participant
- Failure to obtain informed consent or assent from the participant, legal guardian, or other legally authorized representative prior to performing protocol-specified procedures
- Performing procedures not specified in the IRBapproved protocol and not otherwise clinically indicated for the participant

Examples of <u>Reportable</u> Protocol Deviations (2)

- Knowingly reporting of an inaccurate laboratory result
- Failure to follow protocol-specified procedures for participant safety monitoring, management, or reporting (including failure to report expedited adverse events within 3 reporting days)
- Breach of participant confidentiality

Questions? Or not sure about reportability?

If your site has questions about a deviation, email the protocol Clinical Trials Specialists or the Deviation Group: <u>IMPAACT.deviation@fstrf.org</u>



Overview of Today's Discussion

- Key resources
- Definitions
- Policy requirements for protocol deviations considered reportable by IMPAACT ("reportable deviations")
- Procedures for reportable deviations
- Scenarios
- Questions

Procedures for Reportable Protocol Deviations

- Report within 10 working days of site awareness
- Complete and enter a protocol deviation case report form (CRF) into the database <u>AND</u> email a copy of the completed CRF to <u>IMPAACT.deviation@fstrf.org</u>
- Email any additional supplemental documents (e.g., IRB correspondence) with the completed CRF
- See network MOP for exceptions for deviations involving >25 participants or not involving specific participants

Where is the CRF Located?

www.frontierscience.org

eData Studies:

Case Report Forms Annotated Forms CRF Appendix Codes CRFs/Schedules Diagnoses DNRD List Drug Code Lookup Forms Instructions Forms Management Utility Forms Manual Protocol Deviation Form QOL/Adherence Forms **Medidata Rave Studies:**

Site Support Computer Account Report Computing Manual Computing Requirements DMC Contacts Email Address Book Download Email Address Lookup Medidata Rave Resources Newslines People List Training Pages

P1115 Resources

P1115 eCRF Completion Guide

P1115 Print Matrix (blank eCREs)

P1115 DEV0001 Protocol Deviation eCRF (blank eCRF)

eCRF in Medidata Rave

Site Awareness Date (dd-mmm-yyyy)	
Form Week	
Step Number	
NOTE: For a deviation that applies to a single date, please enter the sam	e date for both the start and stop dates below.
Deviation start date (dd-mmm-yyyy):	
Deviation stop date (dd-mmm-yyyy):	
Has or will this deviation be reported to local IRB/EC?	Yes No
Has or will this deviation be reported to DAIDS as a critical event?	Yes No
Type of deviation:	Inappropriate enrollment
	Failure to follow trial randomization or blinding procedures Study product management deviation
	Study product dispensing error
	Conduct of non-protocol procedure
	Breach of confidentiality
	Physical assessment deviation
	Lab assessment deviation
	Use of non-IRB/EC-approved materials
	Informed assent/consent process deviation
	Other
NOTE: Please include the following information in your description belo	
 Explain the reason for deviation 	
Risk/benefit ratio for the participant(s)	
Integrity of the research data	
Participant's willingness (or parent/legal guardian's willingness) to continue	study participation
Description of deviation [800]:	
Describe any corrective actions taken to address this deviation [800]:	
Describe any preventive actions taken to prevent recurrence [800]:	
Deviation reported by (staff name) [70]:	
NOTE: The deviation should be reported by the responsible/communicating	site staff member (IoR or other designee).

PROTOCOL DEVIATION NIAID AIDS CLINICAL TRIALS GROUP

DEV0001/11-04-16

Page 1 of 2

	Patient Number	
eData	Protocol Number	
	Form Week **Seq No.	
CRF –	NOTE: For a deviation that applies to a start and stop dates below.	
	Deviation start date (dd/mmm/yyyy):	
Page 1	Deviation stop date (dd/mmm/yyyy):	
	Has or will this deviation be reported to loc	
	Has or will this deviation be reported to DA	
	Type of deviation	
	Description of deviation: NOTE: Please include the following inf • Explain the reason for deviation • Risk/benefit ratio for the participant(s) • Integrity of the research data • Participant's willingness (or parent/leg	
	[100]:	
	[100]:	
	[100]:	

t Number
col Number Institution Code
Week ***Seq No. ***Step No. Key Operator Code
E: For a deviation that applies to a single date, please enter the same date for both the start and stop dates below.
ation start date (dd/mmm/yyyy):
ation stop date (dd/mmm/yyyy):
or will this deviation be reported to local IRB/EC?
or will this deviation be reported to DAIDS as a critical event? (1-Yes, 2-No)
e of deviation
E: Please include the following information in your description below: Explain the reason for deviation
Risk/benefit ratio for the participant(s) ntegrity of the research data
Participant's willingness (or parent/legal guardian's willingness) to continue study participation [100]:
[100]:
(100):
(100)-
[100]:
[100]:

eData CRF – Page 2

		DEV0001/11-04-16 Page 2 of 2		
t. No.	*Seq. No. **Step No. Date dd mmm	 yyyy		
D				
	ective actions taken to address this deviation:			
[100]:				
Describe any preve	entive actions taken to prevent recurrence:			
[100]:				
[100]:				
[100]:				
[100]:				
[100]:				
[100]:				
[100]:				
[100]:				
Deviation reported I	by (staff name):			
[70]:				
	ion should be reported by the responsible/communicating site staff member	(loR or		
Report date (dd/mr	mm/yyyy):			
	Date Form Keyed (DO NOT KEY): / /			

General Instructions

- Enter the form in eData or Medidata Rave, as needed
- Remember to email PDF of completed CRF and supplemental materials to the Operations Center
- Ops and DMC communicate frequently regarding deviations reported:
 - Expectation that data reported to both Ops and DMC will match
 - If there are inconsistencies, they will be queried

Changing or Deleting a Form

eData

- Online Correct
- Delete Form 🌍

Medidata Rave

- Change data and save
- Inactivate form Inactivate

Questions on Protocol Deviation Forms

- Contact the protocol data manager for questions on using eData or Medidata Rave to submit or modify a form
- Contact the Operations Center regarding questions about what to report: <u>IMPAACT.deviation@fstrf.org</u>

Procedures for Reportable Protocol Deviations

- You will receive a confirmation message within 24-48 hours of emailing
- If the deviation is reportable:
 - The deviation report will be sent by the
 Operations Center to Network Leadership
 - The Operations Center will follow-up with the site on any further clarifications and next steps

Procedures for Reportable Protocol Deviations

- If the Operations Center assesses the deviation as not reportable:
 - The Operations Center will communicate this assessment to the site
 - However, the site Investigator of Record (IoR) retains responsibility for final determination of reportability
 - The Operations Center will ask the site to reply with the site IoR's determination

Overview of Today's Discussion

- Key resources
- Definitions
- Policy requirements for protocol deviations considered reportable by IMPAACT ("reportable deviations")
- Procedures for reportable deviations
- Scenarios
- Questions

(1) In a PK study, a participant is reminded over the phone to switch her study drug to morning dosing beginning 3 days before her visit. She confirms her understanding. However, when she comes to the clinic for the PK visit, she reports her last dose of study drug was last night.



(1) In a PK study, a participant is reminded over the phone to switch her study drug to morning dosing beginning 3 days before her visit. She confirms her understanding. However, when she comes to the clinic for the PK visit, she reports her last dose of study drug was last night.

Not reportable because the deviation is due to participant non-compliance

(2) Hair collection for study drug levels was missed for one participant



(2) Hair collection for study drug levels was missed for one participant

Likely not reportable because the deviation only involved one missed collection from one participant

(3) Hair collection for study druglevels was missed for allparticipants enrolled at the site



(3) Hair collection for study drug levels was missed for all participants enrolled at the site

Likely reportable because the deviation involves all participants at the site and may effect data integrity

(4) During a monitoring visit, aninformed consent form is identifiedas having an incorrect year in thedate of signature



(4) During a monitoring visit, aninformed consent form is identifiedas having an incorrect year in thedate of signature

Likely not reportable because is an administrative error not otherwise associated with increased risk to the participant

(5) During a monitoring visit, an informed consent form is identified as not signed by the participant



(5) During a monitoring review, one informed consent form is not signed by the participant

Likely reportable because of the significance of the omission with respect to GCP compliance and potential risk to the participant

(6) Three participants did not have a screening HIV RNA assay performed within the time period specified in the study inclusion criteria



(6) Three participants did not have a screening HIV RNA assay performed within the time period specified in the study inclusion criteria

Likely reportable because of the significance of the error with respect to eligibility, potential risks to the participants, and potential impacts on data integrity

(7) For a study in which the protocol-specified window for the Labor and Delivery (L/D) visit is 3 days after delivery, all participants at the site were scheduled for their L/D visit 5 days after delivery



(7) For a study in which the protocol-specified window for the Labor and Delivery (L/D) visit is 3 days after delivery, all participants at the site were scheduled for their L/D visit 5 days after delivery

Likely reportable because of the significance of the error with respect to data integrity (and potential risk to the participants)

(8) Participant 630 wasinadvertently given study drugintended for Participant 360(the PIDs were similar)



(8) Participant 630 wasinadvertently given study drugintended for Participant 360(the PIDs were similar)

Likely reportable because of the significance of the error with respect to data integrity and potential risk to the participant

Key Resources

- US Code of Federal Regulations (<u>www.ecrf.gov/</u>)
 - 21 CFR 312.60 45 CFR 46.103(b)(4)(iii)
 - 21 CFR 58.108 45 CFR 46.103(b)(5)
 - 45 CFR 46.113
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (<u>http://ichgcp.net/</u>)
- US Food and Drug Administration (<u>www.fda.gov</u>)
- US Health and Human Services (<u>www.hhs.gov/ohrp/</u>)



Questions?

If your site has questions about a deviation, email the protocol clinical trials specialists or the Deviation Group: <u>IMPAACT.deviation@fstrf.org</u>